| Biomarker ID | 162 |
| PMID | 16618727 |
| Year | 2006 |
| Biomarker | SMPDL3B (Sphingomyelinase like phosphodiesterase 3B) [SMPDL3B 2030] |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-NRK human kinase ARCHS4 coexpression, ROR1 human kinase ARCHS4 coexpression,EPHA1 human kinase ARCHS4 coexpression |
| Experiment | Cancerous Tissue Vs Normal Tissue |
| Type of Biomarker | Diagnostic |
| Cohort | Two sets of Patients were included in the study. Set 1 included 10 cancerous, and 6 normal tissues. Set 2 included 12 cancerous and 10 normal tissues |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | 2.32E-08 |
| Method Used | RT-PCR and qPCR |
| Clinical | No |
| Remarks | Brackets indicate ISOFORMS of the mRNA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SMPDL3B |